Status:
NO_LONGER_AVAILABLE
Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy
Lead Sponsor:
Hope Biosciences Research Foundation
Conditions:
Cerebral Palsy
Eligibility:
MALE
3+ years
Brief Summary
This is an Individual Patient Expanded Access Protocol of Autologous HB-adMSCs for the Treatment of Cerebral Palsy (CP) with the primary goal of treating 1 individual with CP who has exhausted all tre...
Detailed Description
Once the eligibility is confirmed, approximately 1-3 weeks after the screening/baseline visit, the subject will return for the first infusions. Subsequent treatments will occur every other week. On e...
Eligibility Criteria
Inclusion
- Diagnosis of Cerebral Palsy
- 3 years and older.
Exclusion
- Recent or ongoing infection
- Clinically significant cardiovascular, lung, renal, hepatic, or endocrine disease.
- Immunosuppression as defined by WBC \< 3, 000 cells/ml at baseline screening.
- Other acute or chronic medical conditions that, in the opinion of the investigator, may increase the risks associated with study participation or HB-adMSC administration.
- Participation in other interventional research studies.
- Unwillingness to return for follow-up visits.
Key Trial Info
Start Date :
Trial Type :
EXPANDED_ACCESS
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04029896
Last Update
September 29 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hope Biosciences Stem Cell Research Foundation
Sugar Land, Texas, United States, 77478